tbuckley/cabot-search huggingface dataset:
Effectiveness of Simeprevir Treatment for Hepatitis C in Real Practice: Preliminary Results from the Stily Italian Observational Study
Authors: G.B. Gaeta, B. Menzaghi, G. D’Offizi, A. Giorgini, A. Lazzarin, S. Babudieri, M. Brunetto, S. Fagiuoli, L. Simoni, M. Palma, R. Termini
Journal: Journal of Hepatology (2016)
Mir-B-Index: A Candidate Bio-Marker to Identify the Immune Control of HBV Infection in Chronic Hepatitis B Patients Treated with Nucleos(t)ide-Analogues
Authors: D. Cavallone, F. Oliveri, P. Colombatto, B. Coco, V. Romagnoli, L. Surace, S. Fabiani, G. Ricco, F. Moriconi, F. Bonino, M.R. Brunetto
Journal: Journal of Hepatology (2016)
High Efficacy of Sofosbuvir/Velpatasvir/GS-9857 with or without Ribavirin for 12 Weeks in Direct Acting Antiviral-Experienced Patients with Genotype 1 HCV Infection
Authors: E. Lawitz, F. Poordad, J. Wells, R.H. Hyland, Y. Yang, H. Dvory-Sobol, L.M. Stamm, D.M. Brainard, J.G. McHutchison, C. Landaverde, J. Gutierrez
Journal: Journal of Hepatology (2016)
Margaret McCartney: The NHS can’t afford more litigation
Authors: Margaret McCartney
Journal: BMJ (2016)

Things go wrong in the NHS every day. Complaints to the General Medical Council by the public rose from 3858 in 2010 to 5808 in 2014.1 The NHS Litigation Authority has, compared with last year, nearly doubled the money it sets aside for future claims to £56.4bn (€65.9bn; $73.6bn), having paid out £1.4bn in the past year.2 (The NHS annual budget is £116bn.3)

Doctors are encouraged to be honest about errors that cause harm: this ethical position predated duty of candour, which legally requires doctors to do this (it’s likely to become law in Scotland, too). To prevent avoidable mistakes we must be …
Interplay of Matrix Stiffness and c-SRC in Hepatic Fibrosis
Authors: J. Görtzen, R. Schierwagen, J. Bierwolf, S. Klein, F.E. Uschner, P. van der Ven, D. Fürst, C. Strassburg, W. Laleman, J.-M. Pollok, J. Trebicka
Journal: Journal of Hepatology (2016)
Genetic Alterations In Immune Cell Crosstalk Genes In Diffuse Large B-Cell Lymphoma Predict Survival
Authors: Daisuke Ennishi, Fong Chun Chan, David W. Scott, Christoffer Hother, Barbara Meissner, Merrill Boyle, Ryan D Morin, Laurie H. Sehn, Marco A. Marra, Joseph M. Connors, Christian Steidl, Randy D. Gascoyne
Journal: Blood (2013)
No immune graft loss under an ab initio steroid-free immunosuppressive protocol; a two year follow-up
Authors: Jacques Pirenne, R Aerts, Takaaki Koshiba, Frank Van Gelder, Tania Roskams, Miet Schetz, Peter Lauwers, Werner Van Steenbergen, C Verslype, P Yap, Johan Fevery, Frederik Nevens
Journal: Hepatology (2001)
Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013
Authors: Kasia J. Lipska, Xiaoxi Yao, Jeph Herrin, Rozalina G. McCoy, Joseph S. Ross, Michael A. Steinman, Silvio E. Inzucchi, Thomas M. Gill, Harlan M. Krumholz, Nilay D. Shah
Journal: Diabetes Care (2016)

OBJECTIVE To examine temporal trends in utilization of glucose-lowering medications, glycemic control, and rate of severe hypoglycemia among patients with type 2 diabetes (T2DM). RESEARCH DESIGN AND METHODS Using claims data from 1.66 million privately insured and Medicare Advantage patients with T2DM from 2006 to 2013, we estimated the annual 1) age- and sex-standardized proportion of patients who filled each class of agents; 2) age-, sex-, race-, and region-standardized proportion with hemoglobin A1c (HbA1c) &amp;lt;6%, 6 to &amp;lt;7%, 7 to &amp;lt;8%, 8 to &amp;lt;9%, ≥9%; and 3) age- and sex-standardized rate of severe hypoglycemia among those using medications. Proportions were calculated overall and stratified by age-group (18–44, 45–64, 65–74, and ≥75 years) and number of chronic comorbidities (zero, one, and two or more). RESULTS From 2006 to 2013, use increased for metformin (from 47.6 to 53.5%), dipeptidyl peptidase 4 inhibitors (0.5 to 14.9%), and insulin (17.1 to 23.0%) but declined for sulfonylureas (38.8 to 30.8%) and thiazolidinediones (28.5 to 5.6%; all P &amp;lt; 0.001). The proportion of patients with HbA1c &amp;lt;7% declined (from 56.4 to 54.2%; P &amp;lt; 0.001) and with HbA1c ≥9% increased (9.9 to 12.2%; P &amp;lt; 0.001). Glycemic control varied by age and was poor among 23.3% of the youngest and 6.3% of the oldest patients in 2013. The overall rate of severe hypoglycemia remained the same (1.3 per 100 person-years; P = 0.72), declined modestly among the oldest patients (from 2.9 to 2.3; P &amp;lt; 0.001), and remained high among those with two or more comorbidities (3.2 to 3.5; P = 0.36). CONCLUSIONS During the recent 8-year period, the use of glucose-lowering drugs has changed dramatically among patients with T2DM. Overall glycemic control has not improved and remains poor among nearly a quarter of the youngest patients. The overall rate of severe hypoglycemia remains largely unchanged.
Activated Fibroblasts Recovered from the Cirrhotic Liver Provide Malignancy-Prone Phenotypes to Cancer Cells and Macrophages: Comparable Capacity with Cancer-Associated Fibroblasts in Hepatocellular Carcinoma
Authors: Y. Mano, S. Yoshio, H. Shoji, M. Sugiyama, Y. Osawa, K. Kimura, K. Shirabe, Y. Maehara, M. Mizokami, T. Kanto
Journal: Journal of Hepatology (2016)
Dexamethasone, Cytarabine and Cisplatin or Oxaliplatin Schedule (DHAP or Ox-DHA) Is Effective and Widely Applicable in Chronic Lymphocytic Leukemia and Waldenström Macroglobulinemia.
Authors: Marco Ruella, Irene Ricca, Angela Gueli, Daniela Gottardi, Daniele Caracciolo, Luciana Bergui, Paolo Gavarotti, Alberto De Crescenzo, Lucia Farina, Paolo Corradini, Corrado Tarella
Journal: Blood (2009)
Colour stabilities of three types of orthodontic clear aligners exposed to staining agents
Authors: Chen-Lu Liu, Wen-Tian Sun, Wen Liao, Wen-Xin Lu, Qi-Wen Li, Yunho Jeong, Jun Liu, Zhi-He Zhao
Journal: International Journal of Oral Science (2016)

The aim of this study was to evaluate and compare the colour stabilities of three types of orthodontic clear aligners exposed to staining agents in vitro. Sixty clear orthodontic aligners produced by three manufacturers (Invisalign, Angelalign, and Smartee) were immersed in three staining solutions (coffee, black tea, and red wine) and one control solution (distilled water). After 12-h and 7-day immersions, the aligners were washed in an ultrasonic cleaner and measured with a colourimeter. The colour changes (ΔE*) were calculated on the basis of the Commission Internationale de I'Eclairage L*a*b* colour system (CIE L*a*b*), and the results were then converted into National Bureau of Standards (NBS) units. Fourier transformation infrared (FT-IR) spectroscopy and scanning electron microscopy (SEM) were conducted to observe the molecular and morphologic alterations to the aligner surfaces, respectively. The three types of aligners exhibited slight colour changes after 12 h of staining, with the exception of the Invisalign aligners stained with coffee. The Invisalign aligners exhibited significantly higher ΔE* values (ranging from 0.30 to 27.81) than those of the Angelalign and Smartee aligners (ΔE* values ranging from 0.33 to 1.89 and 0.32 to 1.61, respectively, P<0.05). FT-IR analysis confirmed that the polymer-based structure of aligners did not exhibit significant chemical differences before and after the immersions. The SEM results revealed different surface alterations to the three types of aligner materials after the 7-day staining. The three types of aesthetic orthodontic appliances exhibited colour stability after the 12-h immersion, with the exception of the Invisalign aligners stained by coffee. The Invisalign aligners were more prone than the Angelalign and Smartee aligners to pigmentation. Aligner materials may be improved by considering aesthetic colour stability properties.
A culturally adapted, multidisciplinary psychoeducation program for early-stage breast cancer survivors in Asia: A randomized, controlled trial.
Authors: Alexandre Chan, Terence NG, Suan Kai Oh, Tewodros Eyob, Maung Shwe, Yan Xiang Gan, Raymond Chan, Rebecca Alexandra Dent, Raymond C.H. Ng, Mabel Tan, Brandon Goh, Yee Pin Tan, Gilbert Fan
Journal: Journal of Clinical Oncology (2016)

10080 Background: As cancer mortality rates improve in Asia, there is an increasing need to improve the transition to post-treatment survivorship care. However, culturally appropriate standardized survivorship programs are lacking in this region. This study aimed to evaluate the effectiveness of a culturally adapted psychoeducation program (PE) compared with usual care (UC) to reduce distress and symptoms in Asian breast cancer survivors who have completed adjuvant chemotherapy. Methods: This was a randomized, controlled trial in 72 Asian early-stage breast cancer survivors who were randomized into either the PE (n = 34) or the UC (n = 38) arms. Participants in the PE arm underwent a weekly multidisciplinary psychoeducation program, delivered in a group format over 3 weeks, based on current recommendations from the United States Institute of Medicine, coupled with cultural adaptation. Both arms were assessed at baseline and 2 months post-intervention using the Rotterdam Symptom Checklist and EORTC-QLQ-C30. Effect sizes were calculated using Cohen’s d. Results: The mean age ± SD of all participants was 53.0 ± 8.9 years, with majority being Chinese (84.7%) and Malay (6.9%). At baseline, clinical characteristics and outcome measures were well balanced in both arms. Comparing to UC, there was a significant lower levels of physical symptom distress (d= 0.76, p = 0.01) and fatigue (d= 0.49, p = 0.04). There was also a trend towards less appetite loss (d= 0.46, p = 0.06), less constipation (d= 0.45, p = 0.06) and activity level improvement (d= 0.37, p = 0.14) in the PE arm comparing to the UC arm. Conclusions: A culturally adapted, multidisciplinary psychoeducation program was effective to reduce physical distress and symptoms in Asian breast cancer survivors. Clinical trial information: NCT02600299.
Both Biochemical Hepatitis and Cholestasis at Six Months after Liver Transplantation Predict Recurrent Primary Biliary Cholangitis
Authors: A.J. Montano-Loza, D. Roccarina, D. Thorburn, C. Corpechot, J. Dumortier, A. Bosch, E. Giostria, Y. Calmus, I. Franceschet, A. Floreani, A. Mason
Journal: Journal of Hepatology (2016)
Let-7a; A Single Microrna with Opposing Cell-Specific-Tumorigenic Action in both Natural Killer Cells and their Target Hepatocytes
Authors: A.A. Bassiouni, M.M. Abdelrahman, A.I. Gomaa, I. Waked, H.M. El Tayebi, A.I. Abdelaziz
Journal: Journal of Hepatology (2016)
Preliminary results from a randomized phase III trial of adjuvant interleukin-2, interferon alpha and 5-fluorouracil in patients with a high risk of relapse after nephrectomy for renal cell carcinoma (RCC)
Authors: M. Aitchison, C. Bray, H. Van Poppel, R. Sylvester, J. Graham, C. Innes, L. McMahon, P. A. Vasey
Journal: Journal of Clinical Oncology (2008)

5040 Background: Despite an apparently curative resection, 30% of patients with RCC will develop metastases. Histological risk factors can predict those at highest risk. The role of adjuvant treatment remains unclear. The aim of the present study was to determine if triple therapy improves disease free (dfs) or overall survival (os). Methods: Patients 8 weeks post nephrectomy for RCC without macroscopic residual disease with stage T3b-c,T4 or any pT and pN 1 or pN 2 or positive microscopic margins or microscopic vascular invasion, and no metastases were randomised to receive either adjuvant treatment (regimen in table below) or to observation only. Quality of life was assessed by EORTC QLQ C-30. Treatment delivery and toxicity were monitored. The trial was designed to detect an increase in 3 year dfs from 50 % in controls to 65 % on treatment (hazard ratio (HR)=0.63) with 90% power and 2-sided alpha = 0.05; this requires 308 patients and 200 events. Preliminary data release has been approved by the IDMC. Results: From1998 to 2007, 309 patients were randomised (67% male/33% female) 155 to the control arm (median age 55) and 154 to treatment (median age 57). 35% did not complete the treatment, primarily due to toxicity (92% of patients experienced > grade 2, 41%> gd 3). There were no statistically significant differences between the two arms at 6 months in any QoL parameters apart from increased fatigue on the treatment arm (p=.042). At this preliminary analysis 147 patients have relapsed with 3 year dfs of 50% with control versus 60% with treatment (overall HR 0.87, 95% confidence interval (ci) 0.63–1.20).OS at 5 years is 60% for control and 68% with treatment (HR 0.91, 95% ci 0.60 -1.38) Conclusions: The treatment is associated with significant toxicity. This preliminary analysis based on 74% of required events indicates no large benefit for the regime in terms of disease free or overall survival. Adjuvant treatment regimen Drug Dose Weeks Days IL-2 s.c. (MIU/m2) 20 1,4 3,4,5 IL-2 s.c. (MIU/m2) 5 2,3 1,3,5 IFN-∝ s.c. (MIU/m2) 6 1,4 1 IFN-∝ s.c. (MIU/m2) 6 2,3 1,3,5 IFN-∝ s.c. (MIU/m2) 9 5–8 1,3,5 5-FU i.v. bolus (mg/m2) 750 5–8 1 No significant financial relationships to disclose.
A phase II study of cabazitaxel in patients with urothelial carcinoma who have disease progression following platinum-based chemotherapy.
Authors: Jean H. Hoffman-Censits, David J. Vaughn, Jianqing Lin, Stephen Michael Keefe, Naomi B. Haas, William Kevin Kelly, Terry Hyslop, Monica McGuire, Janelle Robinson, Kattie Khadar, Swati Nanda, Brooke Kennedy, Andrea Borghese Apolo
Journal: Journal of Clinical Oncology (2014)

e15519 Background: There is no standard second line therapy for metastatic urothelial cancer (mUC) following platinum chemotherapy (CT). Taxanes have shown clinical activity in this setting. Cabazitaxel is a taxane exhibiting preclinical anti-tumor activity in docetaxel-sensitive and -resistant tumors, and survival benefit in advanced prostate cancer. This two stage phase II trial was designed to assess the efficacy and tolerability of cabazitaxel in patients (pts) with mUC and progression following platinum CT. Methods: Pts with mUC and measurable progression following platinum CT, CrCl >50, and ECOG performance status (PS) < 2 were eligible. Cabazitaxel was administered IV every 3 weeks, initiated at 20 mg/m2 in cycle 1 with inter-patient escalation to 25 mg/m2in cycle 2 at investigator discretion if the patient had no grade 3/4 toxicity during cycle 1. Pegfilgrastim 6 mg SQ was administered day 2 or 3 in all cycles. Radiographic assessment was performed every three cycles. Primary endpoint was overall response proportion. Results: Fourteen pts (12 male, 2 female) enrolled at 3 sites over 17 months with a median age of 60 (range 41-85) and median PS 0. A median of 2 cycles were administered (range 1-6). Most frequent adverse events included, grade 1-2: fatigue (8), diarrhea (6), anemia (5), nausea (4), neuropathy, increased creatinine, lightheadedness (3); grade 3 fatigue (1), anemia (1), diarrhea (1) and hypophosphatemia (1). One patient had grade 4 sepsis and refractory diarrhea precluding further cycles, and one died of refractory hypoxia, both in cycle 1, and were not evaluable for response. One patient had stable disease for 6 cycles. No CR or PR were observed in the initial 14 patients, and per protocol pre-specified stopping rule, the study did not proceed to the second stage due to lack of efficacy. Conclusions: Cabazitaxel showed limited clinical activity in platinum refractory mUC and toxicity with this dosing schema. Patients with platinum refractory mUC remain a challenging population to treat. Clinical trial information: NCT01437488.
Response to Comment on Narayan. Type 2 Diabetes: Why We Are Winning the Battle but Losing the War? 2015 Kelly West Award Lecture. Diabetes Care 2016;39:653–663
Authors: K.M. Venkat Narayan
Journal: Diabetes Care (2016)

Reacting to the hypothesis that the pathogenesis of type 2 diabetes may be fundamentally different in “thin” people developing the disease, Reaven (1) expresses concern that this position does not acknowledge the evidence from his group and others that there may be significant differences in the degree of insulin resistance across racial/ethnic groups that is independent of obesity. Insulin resistance is clearly a major factor in the pathogenesis of type 2 diabetes in all racial/ethnic groups. Furthermore, there is considerable individual variation in the role of obesity on the risk of type 2 diabetes even within ethnic groups. Some have even hypothesized a “personal fat threshold” to explain this variation, suggesting that individuals have a …
High Rates of Svr12 in Adolescents Treated with the Combination of Ledipasvir/Sofosbuvir
Authors: K. Schwarz, K.F. Murray, P. Rosenthal, S. Bansal, C.-H. Lin, L. Ni, B. Kanwar, J. Fraser, P. German, D.M. Brainard, J. Wen, R. Gonzalez-Peralta, M.M. Jonas, W. Balistreri
Journal: Journal of Hepatology (2016)
Intensive Chemotherapy Does Not Prolong Survival Compared to 5-Azacitidine in Patients Aged 70 Years or More with Untreated Acute Myeloid Leukemia
Authors: Luca Maurillo, Francesco Buccisano, Gianluca Gaidano, Mariagiovanna Cefalo, Giovanna Mansueto, Monia Lunghi, Annapaola Campana, Alfonso M D'Arco, Pellegrino Musto, Adriano Venditti
Journal: Blood (2012)
The Marginal Microtubule Coil in the Resting Blood Platelet Is a Dynamic Bipolar Array.
Authors: Joseph E. Italiano, Jennifer L. Richardson, Harald Schulze, Ksenija Drabek, Chloe Bulinski, Niels Galjart, Ramesh A. Shivdasani, John H. Hartwig, Sunita R. Patel
Journal: Blood (2005)
Exposure-Response Relationship of Obeticholic Acid for Alkaline Phosphatase and Total Bilirubin in Patients with Primary Biliary Cirrhosis
Authors: J.E. Edwards, C. LaCerte, L.H. Pheng, T. Peyret, N.H. Gosselin, J.F. Marier, D. Shapiro
Journal: Journal of Hepatology (2016)
Sorafenib Potently Inhibits ETV6-PDGFRβ and FLT3 Mutants, and Shows Activity Against FLT3 Mutants That Are Resistant to Other Small Molecule Inhibitors.
Authors: Els Lierman, Idoya Lahortiga, Helen Van Miegroet, Nicole Mentens, Peter Marynen, Jan Cools
Journal: Blood (2006)
The role of French gastroenterologists (GE) in digestive oncology: Results of a national survey (FFCD, FSMAD, AFEF, ANGH, CREGG, SFED, SNFGE).
Authors: J. Legoux, P. Rougier, P. Pienkowski, R. Faroux, B. Napoléon, O. Rosmorduc, G. Cadiot, F. Ricard, P. Michel, L. Bedenne
Journal: Journal of Clinical Oncology (2010)

e16503 Background: A collaborative work between medical oncologists and gastroenterologists (GEs) seems to be necessary in digestive oncology. So each partner gives his specific knowledge to the patients. The aim of this survey was to analyze the role of French GEs in the care of patients with digestive cancers. Methods: Between October 2007 and March 2008, 3,714 anonymous questionnaires were sent to French GEs, determining their profile, use of chemotherapy and involvement in therapeutic trials. Statistical analysis was carried out in the FFCD data center. Results: We collected 1,663 responses (45%). Responders were from private practices (48%), general hospitals (GH) (27%) and academic hospitals (AH) (15%). Among the responders, 24% of the GEs from private practice, 40% from GH, and 55% from AH said they devoted more than 30% of time to digestive oncology. Most of the GEs (89%) participated weekly or twice weekly in multidisciplinary staff meetings. Indications for chemotherapy were identified by 886 GEs (53%). Chemotherapy prescriptions were carried out by 591 GEs, 364 GEs (22%) prescribed all courses of chemotherapy that they carried out, whereas 227 (14 %) prescribed only some of the courses. Involvement in clinical trials was reported by 476 GEs. Most of these trials took place in Centres de Lutte Contre le Cancer (87%) or AH (74%); a smaller proportion involved GH (28%) and private clinics (13%). The geographic analysis including the prevalence of colonic cancers in France showed that the proportion of GEs prescribing chemotherapy was higher in regions with fewer oncologists (oncologists + GE-oncologists) per inhabitant with colonic cancer. Conclusions: Digestive oncology now accounts for a major part of the activity of many French GEs. The GEs and oncologists seem to play complementary roles in chemotherapy, with a special involvement of the GEs in areas poor in oncologists. No significant financial relationships to disclose.
Prospective Analysis of Early Hospital Readmissions in Patients with Decompensated Cirrhosis and its Impact on Mortality
Authors: L. Franco, J. Ferrusquía, S. Antón, A. Ríos, C.A. Navascués, J. de la Vega, L. Gonzalez-Dieguez, M. Varela, V. Cadahía, M. Rodriguez
Journal: Journal of Hepatology (2016)
An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma.
Authors: Gilles A. Salles, Ajay K. Gopal, Peter Martin, Robert Marcus, Georg Hess, Pier Luigi Zinzani, Tahamtan Ahmadi, Sen Hong Zhuang, Ronald Levy
Journal: Journal of Clinical Oncology (2013)

TPS8614^ Background: Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma (NHL) and comprises approximately 22% of all NHL cases. Most patients treated eventually relapse and subsequent responses and duration of responses become shorter. Patients ultimately become resistant to chemoimmunotherapy and repeated treatment-related toxicity commonly outweighs the benefit of treatment. Ibrutinib is a potent inhibitor of BTK (downstream of the B-cell receptor, BCR) that binds covalently to Cys-481 in the active site, abrogating intrinsic survival pathways (eg, ERK1/2, NF-kB, AKT) as well as survival signals from the microenvironment (eg, TNF family members: BAFF, CD40L; cytokines from T-cells: IL4, IL6, IL10, TNFα). Irish et al (2010) have also shown that up to 60% of FL patients display BCR signaling addiction. Early indications from study PCYC-04753 suggest activity of the BTK inhibitor ibrutinib in FL. Three CR and 3 PR were observed in 11 patients at a dose of 2.5 mg/kg or higher that achieved full BTK occupancy (Fowler, ASH 2012). Methods: The DAWN study, PCI-32765FLR2002, is a phase II, single-arm study of ibrutinib in refractory FL. The study aims to enroll 110 patients with chemoimmunotherapy-resistant FL. Patients will receive an oral daily dose of 560 mg ibrutinib. Patients must have been treated with at least 2 prior lines of therapy, at least 1 rituximab-containing combination chemotherapy regimen, and the last prior line of therapy included an anti-CD20 monoclonal antibody-containing chemotherapy regimen. The primary objective of the study is to evaluate the ORR (CR + PR), with secondary objectives of duration of response, progression-free survival, overall survival, and safety. To better understand the mechanism of action of ibrutinib, blood and tumor samples will be collected and, where feasible, characterized by GEP, SMA, IHC, or other technology as applicable. These evaluations aim to identify biomarkers associated with response or resistance to ibrutinib in subjects with FL and results may assist in the development of this drug in this and potentially other indications. Approximately 64 sites in the US and Europe will enroll patients. Enrollment began in 1Q of 2013. Clinical trial information: NCT01779791.